WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104…


Previous articlePT442 – Burning Questions About Burning Man: Mud, Ebola, and the Big Krab Car
Next articleCOMPASS Pathways appoints Daphne Karydas to its Board of Directors